Reader Response: Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial
- PMID: 35940895
- PMCID: PMC10499428
- DOI: 10.1212/WNL.0000000000201002
Reader Response: Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial
Comment in
-
Author Response: Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial.Neurology. 2022 Aug 9;99(6):259. doi: 10.1212/WNL.0000000000201003. Neurology. 2022. PMID: 35940891 No abstract available.
Comment on
-
Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial.Neurology. 2022 Jan 4;98(1):e40-e50. doi: 10.1212/WNL.0000000000012952. Epub 2021 Oct 14. Neurology. 2022. PMID: 34649873 Free PMC article.
References
-
- Lee WY, Chang JW, Nemeth NL, Kang UJ. Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase enhance dopamine delivery after L-3, 4-dihydroxyphenylalanine administration in Parkinsonian rats. J Neurosci. 1999;19(8):3266-3274. doi:10.1523/JNEUROSCI.19-08-03266.1999. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical